EGFR and breast carcinoma: First, activation of GPR30 could transactivate EGFR and downstream signaling, including PI3K, resulting in the promotion of proliferation and migration in breast cancer cell lines [5–7], indicating that GPR30 is a unique receptor, which is linked to multiple factors, as aforementioned, contributing to TAM resistance in breast cancer cells.